```
=> b reg
FILE 'REGISTRY' ENTERED AT 18:09:53 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 SEP 2007  HIGHEST RN 947061-18-9
DICTIONARY FILE UPDATES:  13 SEP 2007  HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l5
L3                STR
```




```
VAR G1=8/15/16/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2   7  13
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L5        239539 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED  381604 ITERATIONS                      239539 ANSWERS
SEARCH TIME: 00.00.02


=> d que sta l13
L3                STR
```




```
VAR G1=8/15/16/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2   7  13
NUMBER OF NODES IS  18
```

STEREO ATTRIBUTES: NONE
L5 239539 SEA FILE=REGISTRY SSS FUL L3
L11 STR



VAR G1=8/15/16/17
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X5 C AT 20

GRAPH ATTRIBUTES:
RSPEC 7 13 2
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
L13 59980 SEA FILE=REGISTRY SUB=L5 SSS FUL L11

100.0% PROCESSED 239539 ITERATIONS 59980 ANSWERS
SEARCH TIME: 00.00.03

=> d que sta l16
L3 STR



VAR G1=8/15/16/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 2 7 13
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L5 239539 SEA FILE=REGISTRY SSS FUL L3
L11 STR



```
VAR G1=8/15/16/17
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1-X5 C  AT  20

GRAPH ATTRIBUTES:
RSPEC   7  13   2
NUMBER OF NODES IS  30

STEREO ATTRIBUTES: NONE
L13        59980 SEA FILE=REGISTRY SUB=L5 SSS FUL L11
L14              STR
```



```
VAR G1=33/34
VAR G2=AK/20/CB/22
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  33
CONNECT IS E2  RC AT  34
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT  33
GGCAT   IS MCY  UNS  AT  34
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1-X5 C  AT  20
ECOUNT  IS E6 C  AT  33
ECOUNT  IS E5 C  E1 N  AT  34

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L16        30343 SEA FILE=REGISTRY SUB=L13 SSS FUL L14

100.0% PROCESSED   59980 ITERATIONS                      30343 ANSWERS
SEARCH TIME: 00.00.01


=> b hcap
FILE 'HCAPLUS' ENTERED AT 18:10:34 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 14 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 13 Sep 2007 (20070913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitstr l19 1-2

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:841775 HCAPLUS
DN 141:350163
TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists
IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 102 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--10315572	A1	20041014	2003DE-1015572	20030405
	AU2004228120	A1	20041021	2004AU-0228120	20040308
	CA---2521201	A1	20041021	2004CA-2521201	20040308
	WO2004089931	A1	20041021	2004WO-EP02353	20040308
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1626967	A1	20060222	2004EP-0718277	20040308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR2004009164	A	20060411	2004BR-0009164	20040308
	CN---1768051	A	20060503	CN 2004-80008572	20040308
	JP2006522035	T	20060928	2006JP-0504584	20040308
	US2006264419	A1	20061123	2005US-0552065	20051005
PRAI	2003DE-1015572	A	20030405		
	2004WO-EP02353	W	20040308		

OS MARPAT 141:350163
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R1 = H, halo, (CH2)nHet, etc.; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, etc.; R3, R4 = H, (CH2)nCOHet, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted monoarom., bicyclic-heterocycle] and their pharmaceutically acceptable salts were prepared For example, sodium triacetoxyborohydride meditated reductive amination of 1-methyl-piperazine and aldehyde II, e.g., prepared from 2-fluoro-α,γ-dioxo-benzenebutanoic Et ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT2A receptor

binding assays, 167-examples of compds. I exhibited IC50 values ranging from 0.015-4.7x10-7M. Compds. I are claimed suitable as ligands of 5-HT receptors.

IT **508219-09-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

RN 508219-09-8 HCAPLUS

CN Piperazine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:841772 HCAPLUS

DN 141:332186

TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.

IN Schadt, Oliver; Arlt, Michael; Finsinger, Dirk; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph

PA Merck Patent GmbH, Germany

SO Ger. Offen., 78 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--10315569	A1	20041014	2003DE-1015569	20030405
	AU2004228124	A1	20041021	2004AU-0228124	20040310
	CA---2521227	A1	20041021	2004CA-2521227	20040310
	WO2004089932	A1	20041021	2004WO-EP02453	20040310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1611122	A1	20060104	2004EP-0718926	20040310
	EP---1611122	B1	20070613		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR2004008986	A	20060328	2004BR-0008986	20040310
	CN---1768052	A	20060503	CN 2004-80008603	20040310
	JP2006522039	T	20060928	2006JP-0504620	20040310
	AT----364601	T	20070715	2004AT-0718926	20040310
	US2007010531	A1	20070111	2005US-0552064	20051005

PRAI 2003DE-1015569 A 20030405
2004WO-EP02453 W 20040310
OS MARPAT 141:332186
GI



I

AB Title compds. [I; R1 = H, A, halo, (CH2)nAr, cycloalkyl, CF3, NO2, cyano, C(NH)NOH, OCF3; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, CF3; R3, R4 = H, (CH2)nCO2R5, (CH2)nCOHet, CHO, (CH2)nOR5, (CH2)nHet, CH:NOA, etc.; R5 = H, A; A = alkyl, alkoxy, alkenyl, alkoxyalkyl; Ar = (substituted) Ph; Het = (aromatic) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; X = N, CH; with provisos], were prepared Thus, [1-(4'-fluorobiphen-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]methyl(1-methylpyrrolidin-3-yl)amine showed 5-HT2A activity with IC50 = 5.14E-10.
IT **380652-94-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists)
RN 380652-94-8 HCAPLUS
CN Phenol, 2-[5-(2-furanyl)-3-methyl-1-phenyl-1H-pyrazol-4-yl]-, acetate (ester) (9CI) (CA INDEX NAME)



=> d bib abs hitstr l19 3

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:279562 HCAPLUS
DN 138:304276
TI Preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases
PA Merck Patent G.m.b.H., Germany; Yamanouchi Pharmaceutical Co.
SO Ger. Offen., 62 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE--10149370	A1	20030410	2001DE-1049370	20011006
WO2003031435	A1	20030417	2002WO-EP10172	20020911
WO2003031435	A8	20030515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU2002342675	A1	20030422	2002AU-0342675	20020911

PRAI 2001DE-1049370 A 20011006
2002WO-EP10172 W 20020911
OS MARPAT 138:304276
GI



I



II



III



IV

AB Title compds. I [X = CH, N; R1 = H, A, halo, etc.; R2 = Ph, p-chlorophenyl; R3, R4 = H, (CH2)nCO2R5, CHO, etc.; R5 = H, A; A = alkyl, alkenyl, alkoxyalkyl, etc.; n = 0-5] and their pharmaceutically acceptable salts were prepared For example, condensation of enamine II e.g., prepared from 1,1-dimethoxy-N,N-dimethylmethanamine and 2-fluoro-β-oxo-benzenepropanoic acid Et ester, and aryl hydrazine III, e.g., prepared from 2-chloro-5-nitropyridine in 3-steps, provided pyrazole IV (no yield provided). In glycine transporter protein inhibition studies, approx. 71-examples of compds. I exhibited IC50 values ranging from 0.15 - 8.7 μM, e.g., the IC50 value of pyrazole IV = 2.5 μM. Compds. I are claimed useful for the treatment of schizophrenia, depression, dementia, etc.

IT **508219-09-8P 508219-31-6P**, 4-[2-[1-Biphenyl-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]-ethyl]morpholine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles as glycine transporter protein inhibitors for the treatment of neurodegenerative diseases)

RN 508219-09-8 HCAPLUS

CN Piperazine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 508219-31-6 HCAPLUS
CN Morpholine, 4-[2-[1-[1,1'-biphenyl]-4-yl-5-(2-fluorophenyl)-1H-pyrazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)



=> b hcap
FILE 'HCAPLUS' ENTERED AT 18:46:36 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 14 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 13 Sep 2007 (20070913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr l35 tot
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d bib abs hitstr l36 tot

L36 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:851793 HCAPLUS
DN 136:5986
TI Preparation of azole inhibitors of cytokine production
IN Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Sciotti, Richard J.; Wagenaar, Frank L.
PA USA
SO U.S. Pat. Appl. Publ., 124 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2001044445	A1	20011122	1999US-0289155	19990408
PRAI	1999US-0289155		19990408		

OS MARPAT 136:5986
GI



I



II

AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph, the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) production and cellular proliferation in stimulated human T cell lines or human peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepared General procedures for preparation of compds. I were described. Thus, the title compound II was prepared
IT **245748-05-4P 245748-10-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azole inhibitors of cytokine production)
RN 245748-05-4 HCAPLUS
CN Pyridine, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitro- (9CI) (CA INDEX NAME)



RN 245748-10-1 HCAPLUS
CN Pyridine, 5-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-nitro- (9CI) (CA

INDEX NAME)



L36 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:659365 HCAPLUS
DN 131:271873
TI Preparation of pyrazoles and triazoles as inhibitors of cytokine production
IN Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Wagenaar, Frank L.; Sciotti, Richard J.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO---9951580	A1	19991014	1999WO-US07766	19990408
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2327185	A1	19991014	1999CA-2327185	19990408
AU---9933879	A	19991025	1999AU-0033879	19990408
EP---1068187	A1	20010117	1999EP-0915341	19990408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP2002510679	T	20020409	2000JP-0542301	19990408
MX2000PA09837	A	20010405	2000MX-PA09837	20001006
PRAI 1998US-0056996	A	19980408		
1999WO-US07766	W	19990408		

OS MARPAT 131:271873
GI



I



II

AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R2 = H, alkyl cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, hetercyclyloxy, hetercyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2,

alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepared and tested as cytokine production inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors. Thus, the title compound II was prepared

IT **245748-05-4P 245748-10-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles and triazoles as inhibitors of cytokine production)

RN 245748-05-4 HCAPLUS
CN Pyridine, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitro- (9CI) (CA INDEX NAME)



RN 245748-10-1 HCAPLUS
CN Pyridine, 5-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-nitro- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b uspatall
FILE 'USPATFULL' ENTERED AT 18:47:05 ON 14 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 18:47:05 ON 14 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:47:05 ON 14 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l38 tot

L38 ANSWER 1 OF 1 USPATFULL on STN
AN 2001:212449 USPATFULL
TI AZOLE INHIBITORS OF CYTOKINE PRODUCTION
IN BAMAUNG, NWE Y., NILES, IL, United States
BASHA, ANWER, LAKE FOREST, IL, United States
DJURIC, STEVAN W., LIBERTYVILLE, IL, United States
GUBBINS, EARL J., LIBERTYVILLE, IL, United States
LULY, JAY R., WELLESLEY, MA, United States
TU, NOAH P., GURNEE, IL, United States
MADAR, DAVID J., GRAYSLAKE, IL, United States
WARRIOR, USHA, GREEN OAKS, IL, United States
WIEDEMAN, PAUL E., LIBERTYVILLE, IL, United States
ZHOU, XUN, PARK CITY, IL, United States
SCIOTTI, RICHARD J., GURNEE, IL, United States
WAGENAAR, FRANK L., GURNEE, IL, United States
PI US-20010044445 A1 20011122
AI 1999US-000289155 A1 19990408 (9)
DT Utility
FS APPLICATION
LREP ABBOTT LABORATORIES, DEPT. 377 - AP6D-2, 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-6050
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 9955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **245748-05-4P 245748-10-1P**
(preparation of azole inhibitors of cytokine production)
RN 245748-05-4 USPATFULL
CN Pyridine, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitro- (9CI) (CA INDEX NAME)



RN 245748-10-1 USPATFULL
CN Pyridine, 5-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-nitro- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 16:07:02 ON 14 SEP 2007)

FILE 'REGISTRY' ENTERED AT 16:07:15 ON 14 SEP 2007
L1 STR
L2 50 L1
L3 STR L1
L4 50 L3
L5 239539 L3 FULL

FILE 'HCAPLUS' ENTERED AT 16:21:13 ON 14 SEP 2007
L6 1 US20070010531/PN

FILE 'REGISTRY' ENTERED AT 16:21:18 ON 14 SEP 2007

FILE 'HCAPLUS' ENTERED AT 16:21:18 ON 14 SEP 2007
L7 TRA L6 1- RN : 174 TERMS

FILE 'REGISTRY' ENTERED AT 16:21:18 ON 14 SEP 2007
L8 174 SEA L7
L9 170 L5 AND L8

FILE 'HCAPLUS' ENTERED AT 16:22:05 ON 14 SEP 2007
L10 3 L9

FILE 'REGISTRY' ENTERED AT 17:36:10 ON 14 SEP 2007
L11 STR L3
L12 50 L11 SAM SUB=L5
L13 59980 L11 FULL SUB=L5
SAV TEM L13 J064C1/A
L14 STR L11
L15 50 L14 SAM SUB=L13
L16 30343 L14 FULL SUB=L13
SAV TEM L5 J064C1B/A
L17 47 L16 AND L8

```
     FILE 'HCAPLUS' ENTERED AT 17:58:57 ON 14 SEP 2007
L18             3 L17
L19             3 L10,L18
L20             1 L19 AND GLYCINE/TI
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 17:59:47 ON 14 SEP 2007
L21             2 E1-2
L22             1 PYRIDINE/CN
L23          4936 46.156.30/RID AND L16

     FILE 'HCAPLUS' ENTERED AT 18:03:25 ON 14 SEP 2007
L24           461 L23
L25           213 L24 AND PD<=20030310
                  SEL HIT RN
                  DEL SEL Y
                  SEL HIT RN 1-20

     FILE 'REGISTRY' ENTERED AT 18:04:31 ON 14 SEP 2007
L26           553 E1-553
L27               STR L14
L28            50 L27 SAM SUB=L16
L29          2389 L27 FULL SUB=L16
                  SAV TEM L29 J064C1C/A
L30         27954 L16 NOT L29

     FILE 'REGISTRY' ENTERED AT 18:20:11 ON 14 SEP 2007
L31          4795 L30 AND 46.156.30/RID
                  SAV TEM L31 J064C1D/A

     FILE 'HCAPLUS' ENTERED AT 18:21:13 ON 14 SEP 2007
L32           449 L31
L33           148 L32 AND PD<=20000310
                  DEL SEL Y
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 18:22:20 ON 14 SEP 2007
L34           588 E1-588

     FILE 'STNGUIDE' ENTERED AT 18:26:28 ON 14 SEP 2007

     FILE 'REGISTRY' ENTERED AT 18:45:21 ON 14 SEP 2007
L35             2 C10H4F6N4O2 AND L34

     FILE 'HCAPLUS' ENTERED AT 18:45:53 ON 14 SEP 2007
L36             2 L35

     FILE 'HCAOLD' ENTERED AT 18:46:13 ON 14 SEP 2007
L37             0 L35

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:46:19 ON 14 SEP 2007
L38             1 L35

=>
```